Letters, Testimony & Comments

November 14, 2005
October 28, 2005
Notices of new systems of records: "Data Collection Secondary to Coverage Decision System," "Anti-Cancer Chemotherapy for Colorectal Cancer System," and "Carotid Artery Stenting System"
October 3, 2005
Dear Governor Doyle: On behalf of the Biotechnology Industry Organization (BIO) and the Wisconsin Biotechnology and Medical Device Association, I am writing to express concern with legislation that has been forwarded to you by the Wisconsin...
September 30, 2005
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability...
September 30, 2005
Comments by BIO; CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)
September 16, 2005
Comments by BIO; CMS-1501-P (Medicare Program; Proposed Changes to Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates) - NonPass-Throughs; Orphan Drugs; Vaccines; and Drug Administration
September 16, 2005
September 7, 2005
I am honored to be part of this celebration of biotechnology in Japan. The turnout and excitement here today speak to the progress the Japanese biotech industry is making on every front: in the research laboratories, in the media, in the halls of...
September 6, 2005
Comments by BIO; CMS-1325-IFC (Medicare Program; Competative Acquisition of Outpatient Drugs and Biologicals Under Part B)
August 8, 2005
Comments by BIO; FDA Draft guidance; Docket 0062, Federal Register: May 10, 2005 (Volume 70, No. 89)
July 26, 2005
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed bioscience companies.
July 13, 2005
Comments by BIO; FDA Docket 2005D-0122